Current Status of Potent Bone Resorption Antagonists
Received Date: Nov 30, -0001 / Accepted Date: Nov 30, -0001 / Published Date: Feb 12, 2015
Since osteoporosis is considered as an important risk factor to the development of bone fractures, the search for effect therapeutic agents for its prevention and maintenance has never stopped. From hormonal replacement, promotion of bone formation, to prevention of bone resorption has all been tried. The most active part has been played by the antiresorptive agents, viz the Bisphosphonates.
Large investments in research have increased the potency of the drug hundreds of folds and remarkably secured a very effective patient compliance to once a year injection. The therapeutic triumph is complicated with serious though infrequent adverse effects with prolonged or high dose administrations. It is therefore appropriate time to realize the exact safety, the favorable dosages, and the duration of treatment of bisphosphonates. Several extended studies on bisphosphonates have given the answers. Bisphosphonate are safe and effective, serious adverse effects are rare and may occur only after prolonged use. Bisphosphonates should be used as preventive agent only for the extreme high risk cases. Preventive therapy could be safer if 3 years of administration could be followed by a rest period of 2-3years.
Keywords: Osteoporosis, Bisphosphonate, Bone resorption
Select your language of interest to view the total content in your interested language
Share This Article
11th World Congress on Orthopedics, Rheumatology & Sports Medicine
July 09-10, 2018 Sydney, Australia
10th Orthopedics & Rheumatology Annual Meeting & Expo
August 30-31, 2018 Toronto, Ontario, Canada
- Total views: 11922
- [From(publication date): 3-2015 - Dec 13, 2017]
- Breakdown by view type
- HTML page views: 8130
- PDF downloads: 3792